Arcutis Biotherapeutics, Inc.
ARQT
$20.43
-$0.29-1.40%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 27.66% | -7.95% | |||
| Total Other Revenue | -- | 0.00% | |||
| Total Revenue | 23.78% | -7.73% | |||
| Cost of Revenue | -15.15% | 27.88% | |||
| Gross Profit | 29.81% | -11.54% | |||
| SG&A Expenses | 8.07% | 11.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.35% | 14.41% | |||
| Operating Income | 40.43% | -221.40% | |||
| Income Before Tax | 37.27% | -136.80% | |||
| Income Tax Expenses | 22.58% | -13.62% | |||
| Earnings from Continuing Operations | 36.61% | -132.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.61% | -132.30% | |||
| EBIT | 40.43% | -221.40% | |||
| EBITDA | 33.63% | -198.26% | |||
| EPS Basic | 37.07% | -130.09% | |||
| Normalized Basic EPS | 37.75% | -134.54% | |||
| EPS Diluted | 37.07% | -130.09% | |||
| Normalized Diluted EPS | 37.75% | -134.54% | |||
| Average Basic Shares Outstanding | 0.76% | 0.90% | |||
| Average Diluted Shares Outstanding | 0.76% | 0.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||